PDCD1 and neoplasm: Our findings showed that tumors responded to anti-PD-1 Ab (2.5 mg/kg), with primary tumor eradication in 2 out of 8 mice, and 37.5% survival at day 59 after tumor implantation (Fig. 2A,B,D).